Insights Into Hodgkin Lymphoma (HL) 2022

Perspectives of community physicians from across the US on the management Hodgkin lymphoma (HL) with regard to clinical and nonclinical factors impacting treatment selection

Northeast – August 20, 2022
Purchase Report

Faculty Chair

Barbara Pro, MD

MD Anderson Cancer Center, Houston, TX, USA

Midwest – September 17, 2022
Purchase Report

Faculty Chair

Joanna Rhodes, MD

Northwell Health, New York, NY, USA

Northwest – November 19, 2022
Purchase Report

Faculty Chair

Krish Patel, MD

Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA

More Information

  • Philadelphia, PA
  • New Jersey, New York, Pennsylvania

More Information

  • Chicago, IL
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • Assess advisors’ current management of cHL
  • Gain insights into advisors’ perceptions of available therapies and understanding of data
  • Understand impact of pathways and other nonclinical factors that may affect treatment selection

GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.